- Home
- BELFA vs VRDN Comparison
BELFA vs VRDN Comparison
Compare BELFA & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BELFA
- VRDN
- Stock Information
- Founded
- BELFA 1949
- VRDN 2006
- Country
- BELFA United States
- VRDN United States
- Employees
- BELFA N/A
- VRDN N/A
- Industry
- BELFA
- VRDN Medical Specialities
- Sector
- BELFA
- VRDN Health Care
- Exchange
- BELFA Nasdaq
- VRDN Nasdaq
- Market Cap
- BELFA 1.6B
- VRDN 1.6B
- IPO Year
- BELFA N/A
- VRDN N/A
- Fundamental
- Price
- BELFA $135.98
- VRDN $23.01
- Analyst Decision
- BELFA
- VRDN Strong Buy
- Analyst Count
- BELFA 0
- VRDN 10
- Target Price
- BELFA N/A
- VRDN $36.78
- AVG Volume (30 Days)
- BELFA 12.6K
- VRDN 1.4M
- Earning Date
- BELFA 10-29-2025
- VRDN 11-13-2025
- Dividend Yield
- BELFA 0.18%
- VRDN N/A
- EPS Growth
- BELFA N/A
- VRDN N/A
- EPS
- BELFA 4.05
- VRDN N/A
- Revenue
- BELFA $594,034,000.00
- VRDN $305,000.00
- Revenue This Year
- BELFA $25.48
- VRDN N/A
- Revenue Next Year
- BELFA $5.57
- VRDN $34,044.63
- P/E Ratio
- BELFA $33.54
- VRDN N/A
- Revenue Growth
- BELFA 6.08
- VRDN 5.90
- 52 Week Low
- BELFA $53.95
- VRDN $9.90
- 52 Week High
- BELFA $141.50
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- BELFA 66.17
- VRDN 58.85
- Support Level
- BELFA $123.58
- VRDN $21.65
- Resistance Level
- BELFA $141.50
- VRDN $23.34
- Average True Range (ATR)
- BELFA 4.59
- VRDN 1.13
- MACD
- BELFA 1.73
- VRDN -0.08
- Stochastic Oscillator
- BELFA 81.40
- VRDN 53.61
About BELFA Bel Fuse Inc.
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).